Early Licensure of a Breakthrough Cancer Drug Gives Hope to Patients

Early Licensure of a Breakthrough Cancer Drug Gives Hope to PatientsNo clinical supply request could be a higher priority than that of a physician urgently seeking an investigational cancer drug for a patient who has exhausted all treatment options.

This compelling case study outlines how a multinational pharmaceutical company worked with a cross-functional Fisher Clinical ServicesSM team to deliver clinical supplies to treat an aggressive form of skin cancer, Merkel cell carcinoma.

These efforts resulted in the FDA fast tracking the investigational drug by granting it breakthrough status and early licensure as a commercial drug.

Resource Library

Related Sites

Additional Resources